Risk factors for domain-specific neurocognitive outcome in pediatric survivors of a brain tumor in the posterior fossa - Results of the HIT 2000 trial - Articles - Oncology · Hematology

Central Nervous System Tumors

Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor

Neuro Oncol

Tohidinezhad F, Zegers CML, Vaassen F, Dijkstra J, Anten M, Van Elmpt W, De Ruysscher D, Dekker A, Eekers DBP, Traverso A

doi: 10.1093/neuonc/noae035

Further Publications

Clinical and molecular risk factors in extracranial malignant rhabdoid tumors - Towards an integrated model of high-risk tumors

Clin Cancer Res

Fincke VE, Steinbügl M, Chun HE, Nemes K, Mucha M, Loßner M, Dorn F, Gastberger K, Bühner S, Sill M, Kröncke T, Siebert R, Melchior P, Furtwängler R, Schlesner M, Vokuhl C, Rocken C, Johann PD, Frühwald MC

doi: 10.1158/1078-0432.CCR-23-3489

Breast Cancer

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

J Clin Oncol

Ganz PA, Bandos H, Španić T, Friedman S, Müller V, Kuemmel S, Delaloge S, Brain E, Toi M, Yamauchi H, de Dueñas EM, Armstrong A, Im SA, Song CG, Zheng H, Sarosiek T, Sharma P, Geng C, Fu P, Rhiem K, Frauchiger-Heuer H, Wimberger P, t'Kint de Roodenbeke D, Liao N, Goodwin A, Chakiba-Brugère C, Friedlander M, Lee KS, Giacchetti S, Takano T, Henao-Carrasco F, Virani S, Valdes-Albini F, Domchek SM, Bane C, McCarron EC, Mita M, Rossi G, Rastogi P, Fielding A, Gelber RD, Scheepers ED, Cameron D, Garber J, Geyer CE, Tutt ANJ

doi: 10.1200/JCO.23.01214

Breast Cancer

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

J Clin Oncol

Bardia A, Rugo HS, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Kalinsky K, Cortés J, Shaughnessy JO, Diéras V, Carey LA, Gianni L, Piccart-Gebhart M, Loibl S, Yoon OK, Pan Y, Hofsess S, Phan SC, Hurvitz SA

doi: 10.1200/JCO.23.01409

Leukemia

Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study

J Clin Oncol

Alexander S, Kairalla JA, Gupta S, Hibbitts E, Weisman H, Anghelescu D, Winick NJ, Krull KR, Salzer WL, Burke MJ, Gore L, Devidas M, Embry L, Raetz EA, Hunger SP, Loh ML, Hardy KK

doi: 10.1200/JCO.23.01989

Central Nervous System Tumors

Neurocognitive outcomes and functional independence in adult survivors of childhood medulloblastoma diagnosed over three decades

Neuro Oncol

Papini C, Mirzaei S S, Xing M, Tonning Olsson I, Salloum R, de Blank PMK, Lange KR, King TZ, Srivastava D, Leisenring WM, Howell RM, Oeffinger KC, Robison LL, Armstrong GT, Krull KR, Brinkman TM

doi: 10.1093/neuonc/noae119

Breast Cancer

Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial

JAMA Oncol

Partridge AH, Hyslop T, Rosenberg SM, Bennett AV, Drier S, Jonsson M, Shimada A, Li Y, Li Y, Lynch T, Frank E, Collyar D, Basila D, Pinto D, Weiss A, Wolf A, Norris K, Witten M, Boisvert M, Giuliano A, Larson KE, Yost K, McAuliffe PF, Krie A, Tamirisa N, Darai S, Carey L, Thompson A, Hwang ES, COMET Study Consortium

doi: 10.1001/jamaoncol.2024.6556

Genitourinary Cancer

Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial

BJU Int

Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S, Linton K, Rajasundaram R, Hussain SA, Catto JWF

doi: 10.1111/bju.16516

Further Publications

Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer

J Clin Oncol

Im C, Neupane A, Baedke JL, Lenny B, Delaney A, Dixon SB, Chow EJ, Mostoufi-Moab S, Yang T, Richard MA, Gramatges MM, Lupo PJ, Sharafeldin N, Bhatia S, Armstrong GT, Hudson MM, Ness KK, Robison LL, Yasui Y, Wilson CL, Sapkota Y

doi: 10.1200/JCO.23.02281

Related content

Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor

Clinical and molecular risk factors in extracranial malignant rhabdoid tumors - Towards an integrated model of high-risk tumors

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression

Impact of Propofol Exposure on Neurocognitive Outcomes in Children With High-Risk B ALL: A Children's Oncology Group Study

Neurocognitive outcomes and functional independence in adult survivors of childhood medulloblastoma diagnosed over three decades

Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ: A Secondary Analysis of the COMET Randomized Clinical Trial

Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial

Trans-Ancestral Genetic Risk Factors for Treatment-Related Type 2 Diabetes Mellitus in Survivors of Childhood Cancer